Surinporn Likhitsathian

Surinporn Likhitsathian

Auto-generated profile, based on publicly available information

Surinporn Likhitsathian

Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
NMNarong Maneeton
Narong Maneeton
BMBenchalak Maneeton
Benchalak Maneeton
PWPakapan Woottiluk
Pakapan Woottiluk
SLSurinporn Likhitsathian
Surinporn Likhitsathian
SSSirijit Suttajit
Sirijit Suttajit
MSManit Srisurapanont
Manit Srisurapanont
Background: Some studies have indicated the efficacy of quetiapine in the treatment of generalized anxiety disorder (GAD). Objective: The purpose of this study was to systematically review the efficacy, acceptability, and tolerability of quetiapine in adult patients with GAD. Methods: The SCOPUS, MEDLINE, CINAHL, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases were searched in April 2015. All randomized controlled trials (RCTs) of GAD were considered to be included in this meta-analysis. All RCTs of quetiapine in GAD patients providing endpoint outcomes relevant to severity of anxiety, response rate, remission rate, overall discontinuation rate, or discontinuation rate due to adverse events were included. The version reports from suitable clinical studies were explored, and the important data were extracted. Measurement for efficacy outcomes consisted of the mean-changed scores of the rating scales for anxiety, and response rate. Results: A total of 2,248 randomized participants in three RCTs were included. The pooled mean-changed score of the quetiapine-treated group was greater than that of the placebo-treated group and comparable to selective serotonin reuptake inhibitors (SSRIs). Unfortunately, the response and the remission rates in only 50 and 150 mg/day of quetiapine-XR (extended-release) were better than those of the placebo. Their response and remission rates were comparable to SSRIs. The rates of pooled overall discontinuation and discontinuation due to adverse events of quetiapine-XR were greater than placebo. Only the overall discontinuation rate of quetiapine-XR at 50 and 150 mg/day and the discontinuation rate due to adverse events of quetiapine-XR at 50 mg/day were comparable to SSRIs. Conclusion: Based on this meta-analysis, quetiapine-XR is efficacious in the treatment of GAD in adult patients. Despite its low acceptability and tolerability, the use of 50–150 mg/day quetiapine-XR for adult GAD patients may be considered as an alternative treatment. Further well-defined studies should be conducted to warrant these outcomes.

23 April 2007 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
MSManit Srisurapanont
Manit Srisurapanont
SLSurinporn Likhitsathian
Surinporn Likhitsathian
VBVudhichai Boonyanaruthee
Vudhichai Boonyanaruthee
CCChawanun Charnsilp
Chawanun Charnsilp
NJNgamwong Jarusuraisin
Ngamwong Jarusuraisin
Not only the prevalence, but also the progress of metabolic abnormalities in schizophrenic patients is of importance for treatment planning and policy making. However, there have been very few prospective studies of metabolic disturbance in schizophrenic patients. This study aimed to assess the progress of metabolic abnormalities in Thai individuals with schizophrenia by estimating their one-year incidence rate of metabolic syndrome (MetS). We screened all schizophrenic patients who visited our psychiatric clinic. After the exclusion of participants with MetS at baseline, each subject was reassessed at 6 and 12 months to determine the occurrence of MetS. The definition of MetS, as proposed by the International Diabetes Federation (IDF), was applied. Fifty-seven participants (24 males and 33 females) had a mean of age and duration of antipsychotic treatment of 37.5 years old and 8.4 years, respectively. At baseline, 13 subjects met the MetS definition. Of 44 subjects who had no MetS at baseline, 35 could be followed up. Seven of these 35 subjects (20.0%) had developed MetS at the 6- or 12-month visit, after already having 2 MetS components at baseline. The demographic data and characteristics of those developing and not developing MetS were not different in any respect. Thai schizophrenic patients are likely to develop MetS. Their metabolic abnormalities may progress rapidly and fulfill the MetS definition within a year of follow-up. These findings support the importance of assessing and monitoring metabolic syndrome in schizophrenic patients.

1 December 2013 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
SLSurinporn Likhitsathian
Surinporn Likhitsathian
KUKanok Uttawichai
Kanok Uttawichai
HBHathaichonnee Booncharoen
Hathaichonnee Booncharoen
AWApisak Wittayanookulluk
Apisak Wittayanookulluk
CAChaisiri Angkurawaranon
Chaisiri Angkurawaranon
MSManit Srisurapanont
Manit Srisurapanont

KTKongprai Tunsuchart
Kongprai Tunsuchart
PLPeerasak Lerttrakarnnon
Peerasak Lerttrakarnnon
KSKriengkrai Srithanaviboonchai
Kriengkrai Srithanaviboonchai
SLSurinporn Likhitsathian
Surinporn Likhitsathian
SSSombat Skulphan
Sombat Skulphan
This study aimed to investigate prevalence and factors potentially associated with diabetes-related distress (DRD) among type 2 diabetes mellitus (T2DM) patients in a primary health care center in Thailand. This cross-sectional study was conducted with a total of 370 patients with T2DM. Data were collected at primary health care centers in Hang Dong District, Chiang Mai Province, Thailand. DRD was assessed using the Diabetes Distress Scale (DDS-17). The association between sociodemographic characteristics and other factors with DRD was analyzed using the Fisher t-test, Chi-square test, and Pearson’s correlation coefficient test. The association between Hemoglobin A1c (HbA1c) and DRD was analyzed using multiple linear regression analysis. The participants had a mean age of 60.95 ± 7.96, and most were female (68.1%). Of the participants with DRD, 8.9% had moderate to high levels of distress. Education level and family support were significantly associated with the overall level of DRD. Additionally, HbA1c and co-morbidity were also significantly associated with DRD, as were emotional burden and regimen distress. Multiple linear regression analysis found that increased HbA1c was positively associated with increased DRD after adjusting for age, sex, education, duration of T2DM, co-morbidity, diabetic complications, and family support. Screening with DRD may be beneficial in T2DM patients.

KTKongprai Tunsuchart
Kongprai Tunsuchart
PLPeerasak Lerttrakarnnon
Peerasak Lerttrakarnnon
KSKriengkrai Srithanaviboonchai
Kriengkrai Srithanaviboonchai
SLSurinporn Likhitsathian
Surinporn Likhitsathian
SSSombat Skulphan
Sombat Skulphan
This study evaluated the short-term efficacy of brief group cognitive behavioral therapy (BG-CBT) in reducing diabetes-related distress (DRD), lowering hemoglobin A1c (HbA1c), improving food consumption behavior, increasing physical activity, and improving medication adherence behavior. A quasi-experimental pretest/post-test design with follow-up assessments was used with an experimental and a control group. Participants were patients with uncontrolled type 2 diabetes mellitus (T2DM) and moderate or high diabetes-related distress recruited from the Diabetes Mellitus Clinic of Hang Dong Hospital, Chiang Mai, Thailand. Fifty-six eligible participants were purposively selected and enrolled, then randomly assigned to either the BG-CBT group or the control group. The BG-CBT group received six brief weekly sessions of cognitive behavioral group therapy, while the control group received conventional care. Baseline data were collected at week 0 (pretest) and at week 6 (post-test), including food consumption behavior, physical activity, and adherence to medication regimes, as well as a blood examination to determine levels of HbA1c at the week 12 follow-up. DRD was assessed using the Diabetes Distress Scale (DDS-17) and analyzed using descriptive statistics, including pair t-test and independence t-test results. The BG-CBT had a significant effect on the amelioration of diabetes distress, improvement of food consumption behavior, and reduction of HbA1c levels, demonstrating the effectiveness of BG-CBT in maintaining diabetes control in people with T2DM-related distress.

27 February 2018 in Drug and Alcohol Review
Verified
Journal Article
Closed access
PDF file
CAChaisiri Angkurawaranon
Chaisiri Angkurawaranon
WJWichuda Jiraporncharoen
Wichuda Jiraporncharoen
SLSurinporn Likhitsathian
Surinporn Likhitsathian
KTKanittha Thaikla
Kanittha Thaikla
MKManop Kanato
Manop Kanato
AAApinun Aramrattana
Apinun Aramrattana